Sign in to view content

Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER

David A. Eichenbaum, MD, FASRS

Video
Published 2021

Related

Expert Panel:PDS
Robert A. Mittra, MD, FASRS
Dante Joseph Pieramici, MD
Aleksandra V. Rachitskaya, MD, FASRS
Margaret A. Chang, MD, MS
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2024
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more